Acute myeloid leukaemia (AML) is a clinically and molecularly heterogeneous disease and its treatment remains challenging since only 30% of patients achieve long-term disease-free survival.
1 Evidence that immunological control contributes to killing of residual leukaemia cells has emerged from allogeneic haematopoietic stem cell transplantation, 2 and immunotherapy holds promise as a possible new treatment, in combination with chemotherapy, to eradicate minimal residual disease.
We recently identified mutations of the nucleophosmin (NPM1) gene as the most common genetic lesion in adult AML, occurring in about one-third of patients.
3 AML carrying NPM1 mutations represents an entity with distinctive biological and clinical features 4 and the unique C-terminal sequences of NPM leukaemic mutants have the potential to serve as target for immunotherapeutic intervention. We addressed this issue using the BLAST web tool (http://www.ncbi.nlm.nih.gov/blast) to search for short sequences matching the NPM mutants A-F. None of the human sequences present in databanks matched that of the 11 C-terminal residues of the NPM mutants, suggesting that this sequence may serve as leukaemia-specific antigen.
A distinguishing feature of the mutated proteins generated by NPM1 mutations is that they are localized in the cytoplasm (instead of the nucleus) of leukaemic cells. 3 This aberrant cytoplasmic expression of the mutants is caused by the concerted action of two alterations that occur at the C-terminus of the NPM protein, that is mutations of tryptophan(s) at position 288 or 290 and acquirement of a new nuclear export signal motif.
5 All NPM leukaemic mutants so far identified (about 40) 4 carry common alterations at their C-terminal region, and two mutants (named A and B) account for about 90% of cases.
4
Dislocation of NPM in the cytoplasm of leukaemic cells may favour the processing of the protein by the class I degradation pathway leading to human leukocyte antigen (HLA) presentation and anti-cancer immune response. Consequently, we tested the binding of candidate peptides to HLA molecules in silico and in vitro.
We first analysed the sequence of wild-type and mutated NPM proteins to identify peptides predicted to bind common HLA class I and class II molecules. For this purpose, the sequences of the wild-type and mutated NPM (A-F) 3 were analysed with the EpiMatrix System software, which models the interaction between candidate peptides (usually 9-mers) and presenting major histocompatibility complex (MHC) molecules.
6 Briefly, each sequence was first parsed into peptides of nine amino acids in length, each overlapping the last by eight residues (for class I analysis, the sequences were also parsed into overlapping 10-mer peptides). Each peptide was then scored for its predicted binding affinity to a panel of six common HLA class I alleles (A*0101, A*0201, A*0301, A*2402, B*0702 and B*4403) and eight common HLA class II alleles (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301 and DRB1*1501). These alleles collectively cover 495% of any subject population. Raw EpiMatrix scores were normalized before reporting. The resulting 'Z' scores are normally distributed and directly comparable across alleles. Based on our previous experience, we have determined that a peptide scoring above 1.28 (approximately the top 10% of any given peptide set) has an increased probability of binding to HLA molecules, a peptide scoring above 1.64 (the top 5%) has a significant probability of binding and a peptide scoring above 2.32 (the top 1%) is highly likely to bind. Previous studies have demonstrated that EpiMatrix accurately predicts published MHC ligands and T-cell epitopes.
7
The EpiMatrix System predicted that several peptides could bind to HLA class I molecules. Table 1 summarizes the results of this in silico analysis showing peptides with scores above 2.32, which suggests a very good HLA binding potential. The highest scores were given for mutant E and F peptides predicted to bind to A*0101 or A*0301. The highest scoring peptides derived from the more common mutation A variant are AVEEVSLRK (restricted by HLA A*0301) and AIQDLCLAV and CLAVEEVSL (both restricted by HLA A*0201). For HLA class II molecules, the wild-type and A-D mutated sequences contain a few potential epitopes. Mutation E has a good epitope at position 11 (WQSLAQVSL), which scores well against four of eight tested class II alleles and in the top 10% for another three. Mutation F also has a very good potential epitope at position 11. These findings point to the potential of NPM mutated peptides for binding to HLA class I molecules.
Based on these results, we next investigated the ability of peptides to bind in vitro to HLA.A2 molecules, using as a probe biotinylated recombinant HLA-A2 molecules identical to those used to prepare tetramers. 8 Focusing on the commonest NPM mutants A and D, three peptides (CLAVEEVSL, AIQDLCLAV and DLCLAVEEV) were selected for testing their in vitro binding to HLA-A*0201 molecules. Briefly, 40 ml of biotinylated HLA-A2 complexes (2 mg/ml in phosphate-buffered saline (PBS)) loaded with peptide GLCTLVAML was added into streptavidin-coated microwells and incubated overnight at 41C. The peptide GLCTLVAML is derived from the BMLF1 protein of EpsteinBarr virus and is known to bind well to HLA-A2. 9 The wells were washed with PBS and the complexes denatured by acidic treatment for 90 s at room temperature with 50 ml of 25 mM sodium citrate and 150 mM NaCl at pH 3.1. The solution was neutralized with 23 ml of 200 mM Tris-HCl and 150 mM NaCl (pH 8.5), and the wells were immediately washed with 300 ml PBS þ 0.5% (w/v) bovine serum albumin (BSA) to remove free b2-microglobulin and peptide. Then 40 ml of 200 mM Tris-HCl, 150 mM NaCl (pH 8.5), containing 4 mg/ml of b2-microglobulin with or without peptide were added and incubated for 7 h at 251C and overnight at 41C to allow refolding of the HLA/ peptide/b2-microglobulin complexes. Peptides were added at the concentrations of 10 nM, 100 nM and 1 mM. Refolded complexes were detected with murine monoclonal antibody W6/32, which requires the presence of both the heavy chain and the b2-microglobulin for binding. 10 Binding of W6/32 was detected using anti-mouse Ig coupled to peroxidase.
Two of the petides, CLAVEEVSL and AIQDLCLAV, bound to HLA-A2 molecules as efficiently as our reference peptide (Figure 1 ). The third peptide (DLCLAVEEV) scored lower on the EpiMatrix scale (Epx score 1.47) and bound only weakly. Assuming that at least one of the two high binding peptides is processed in leukaemic cells, these results suggest that mutated NPM could be targeted by T-lymphocytes restricted by HLA-A2 molecules. We also tested the binding of peptide AVEEVSLRK, encoded by the A and D mutated genes, to HLA-A1 and A3 molecules, with negative results.
AML with NPM1 mutations in the absence of FLT-ITD is characterized by a relatively favourable prognosis. 4 To assess whether the good outcome may reflect an in vivo humoral immune response to the leukaemic NPM mutants, we analyzed the sera from 23 NPM mutated and 5 NPM unmutated AML patients at diagnosis for the presence of anti-NPM wild-type and anti-NPM mutant antibodies. Briefly, each well of 96-well plates (Costar, Cambridge, MA, USA) was coated with 200 ml aliquots of mutated NPM peptide CLAVEEVSLRK (10 mg/ml) or recombinant wild-type NPM (10 mg/ml) for 3 h at room temperature. After washing with PBS Tween 20, wells were blocked for 1 h at room temperature with 200 ml aliquots of PBS þ 1% v/v BSA. Each serum sample was diluted 1/10 in PBS 0.1% v/v Tween 20 and incubated overnight at 41C. Wells were washed three times as described above and incubated for 3 h at room temperature with goat anti-human immunoglobulin antibodies coupled to horseradish peroxidase (Biosource, Camarillo, CA, USA) and diluted 1:250 000 in PBS 0.1% v/v Tween 20. Finally, each well was coated with 100 ml of TMB substrate-chromogen and, after 15 min, the reaction was stopped and absorbance was measured at 655 nm.
No evidence was obtained of a humoral immune response to wild-type NPM or to peptide CLAVEEVSLRK (mutation A) (data not shown). Lack of immune response in AML patients might depend on failure to present NPM peptides or inadequate functioning of a compromised immune system. This view is supported by the observation that recipients of allogeneic bone marrow transplants who develop extensive chronic graft-versushost disease 11 are able to generate an immune response against wild-type NPM, indicating that this molecule is immunogenic. Furthermore, two peptides (CLAVEEVSLRK and QEAIQDLCLA-VEEVSLRK) were successfully used as immunogens to generate rabbit polyclonal antibodies specifically directed against NPM leukaemic mutants.
4,5
The present study indicates that mutated NPM peptides can be presented by HLA molecules, suggesting that AML cells carrying cytoplasmic mutated NPM could induce an antileukaemic T-cell response. Further studies are needed to determine whether the candidate antigenic peptides are processed in leukaemic cells and whether NPM-specific T and B cells can target NPMc þ AML cells. 
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Figure 1
Testing of peptide binding to human leukocyte antigen (HLA)-A2 molecules. Peptides were added at the indicated concentrations to acid-denatured recombinant HLA-A2/peptide/b2-microglobulin complexes, which were biotinylated and bound to avidin-coated microwells. Peptide binding resulted in refolding of the trimeric complex, quantified with the conformational anti-HLA class I monoclonal antibody W6/32 followed by anti-Ig antibodies coupled to peroxidase. Control peptide GLCTLVAML (EpiMatrix score 2.69) is derived from the BMLF1 protein of Epstein-Barr virus. Imatinib mesylate induces complete cytogenetic response (CCR) in more than 85% of newly chronic myeloid leukemia (CML) chronic phase (CP) patients, and a statistical survival benefit over interferon-a treatment has been recently achieved. 1 Yet, some crucial issues about imatinib are still unsolved and we may refer to this pioneering drug as a 'functional recovery' but not a true cure for CML patients. In fact residual molecular disease persists in the majority of patients 2,3 probably due the in vitro evidence that Ph þ quiescent stem cells are insensitive to imatinib. 4 As a clinical consequence, even in those patients in which BCR-ABL transcript is undetectable by the most sensitive nested reverse transcriptase-PCR method (complete molecular response (CMolR)), discontinuation of the drug is followed by disease recurrence in nearly all cases. 5, 6 Not surprisingly BCR-ABL-positive stem cells can still be detected in patients in CCR after short term of imatinib treatment 7 but no data are currently available regarding the real incidence of leukemic precursors persisting in patients after prolonged treatment with this drug. Thus, we evaluated the amount of bone marrow residual CD34 þ /Ph þ cells in 31 CML patients in stable longlasting CCR during imatinib treatment after receiving their informed written consent. The median age was 46 years (range 19-77) with 18 male and 13 female. At imatinib start all patients were in CP, 15/31 were newly diagnosed while 16/31 have been previously refractory (10 patients) or intolerant (6 patients) to interferon-a. At the time of residual CD34 þ /Ph þ evaluation all patients were on 400 mg/day of imatinib for a median time of 39 months (range 24-59), and in stable CCR for a median time of 35 months (range 15-53). Whole bone marrow fluorescence in situ hybridization (FISH) analysis identified Ph þ cells in 11/31 patients (35%; median of 2% nuclei, range 1-4%), while BCR-ABL transcript was still measurable in 24/31 (77%) patients by reverse transcriptase-PCR.
After immunomagnetic sorting of about 10 ml of marrow aspirate, an adequate number of CD34 þ cells (average 9.6 Â 10 5 ) for FISH analysis was collected in all 31 patients and CD34 þ -enriched population was confirmed to be more than 90% pure by flow cytometry analysis. FISH analysis of CD34 þ -purified cells showed the persistence of Ph þ cells in 14/31 (45%) patients with a median number of 1% (range 1-7%). Disease characteristics and follow-up of 14 CD34 þ / Ph þ positive patients and 17 CD34 þ /Ph þ negative patients are listed in Table 1 .
At the time of evaluation, a weak correlation was found between the persistence of leukemic stem cells and the amount of molecular residual disease. In fact bone marrow fusion transcript was still detectable in 12/14 (86%) CD34 þ / Ph þ positive patients and in 12/17 (70%) CD34 þ / Ph þ negative patients. All patients continued imatinib at 400 mg/day and were monitored for their residual disease. Interestingly, after a median follow-up time of 20 months (range 7-36) since CD34 þ evaluation, 4/14 (28%) patients with residual CD34 þ /Ph þ positive cells showed a significant increase in their molecular disease (considered as more than 1 log increase of BCR-ABL/ABL ratio in two consecutive samples) (Table 1, patient #1, 3, 8, 9) . In addition, one of them lost CCR, while 4/14 (28%) were in stable CMolR. On the contrary, only 2/17 (11%) patients without residual Ph þ stem cells showed an increased level of detectable molecular disease during follow-up (Table 1, patient #20, 28) . No patient in this group lost CCR and 9/17 (53%) were in CMolR.
To our knowledge this is the first 'in vivo' evaluation confirming that CML precursors survive during imatinib treatment even after prolonged and stable CCR. Our findings assessed that at least 45% of these patients harbor residual CD34 þ /Ph þ cells, although the role of these cells in the outcome of imatinib-treated CML patients is not clearly definable from our study. Albeit the series of patients is small we found a trend in a rise of molecular residual disease over time in
